<DOC>
	<DOCNO>NCT01627938</DOCNO>
	<brief_summary>This study primarily address question whether combination Mitoxantrone therapy dexrazoxane reduce cardiotoxic side effect treatment Multiple Sclerosis patient comparison Mitoxantrone monotherapy .</brief_summary>
	<brief_title>Study Evaluate Reduction Cardiac Problems Multiple Sclerosis Patients With Mitoxantrone Dexrazoxane Combination</brief_title>
	<detailed_description>It design provide clinical paraclinical efficacy safety data dexrazoxane Mitoxantrone treatment Multiple Sclerosis order investigate possible positive influence dexrazoxane cardiac function Mitoxantrone-affected myocardial tissue possible augmented clinical efficacy Mitoxantrone combination dexrazoxane neurological outcome parameter . The incidence cardiotoxicity combine Mitoxantrone/dexrazoxane treatment investigate compare standard Mitoxantrone-treatment without dexrazoxane .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>Written inform consent participate study Male female subject 18 year age 55 year age Subject must one mention confirm diagnosis Multiple Sclerosis : RRMS CPMS accord rev . McDonald Criteria ( 2005 ) If female childbearing potential : Will practice reliable birth control measure study treatment least 6 month completion study medication ; lactate pregnant ; document negative pregnancy test result within 72 hour prior study medication administration . Male study participant : Will practice reliable birth control measure study treatment least 6 month completion study medication Subject willing participate study , follow protocol study treatment regimen , comply plan assessment Mitoxantrone treatment indication give accord current guideline : Relapsing progressive secondary progressive MS with/without superimpose relapse EDSS 36 ; EDSS deterioration ≥1 point last 18 month 2 relapse nonresponse nontolerability pretreatment ≥ 48 mg/m² BSA MX dose receive baseline visit lifetime dosage study entry . If patient regular ongoing MX treatment , infusion interval 3 month must obtain ( see exclusion criterion ) Concomitant clinically suspect confirmed neurologic disorder study entry may interfere evaluation protocol [ i.e . EDSS , MSFC , MEP MRI measurement ] PreTreatment DRZ immunosuppressive drug anthracycline family cardiotoxic potential MX prior study enrollment Last Treatment MX within past 84 day prior study enrollment ( regular 3monthly interval must obtain ) History hypersensitivity study drug drug similar chemical structure Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive HCG laboratory test ( &gt; 5 mIU/ml ) Unwillingness perform adequate contraception Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever long Subjects unable unwilling adhere studydesignated procedure restriction Patients able perform cardiac/neurological investigation include MRI , e.g . hypersensitivity MRI contrast agent Other know contraindication DRZ MX accord current labelling Subject preexist cardiac disease interfering leave ventricular ejection fraction , i.e . cardiac insufficience different reason ( result prior cardial condition myocardial infarction , myocarditis ) Routine coadministration cortisonepulse therapy ( treatment relapse ) , intrathecal triamcinolonetherapy offlabel/ investigational agent ( e.g . fampridine , aminopyridine ) History malignancy past 5 year ( exclude localize basal cell carcinoma skin ) PreTreatment immunosuppressive drug ( azathioprine , methotrexate , mycophenolate , cyclophosphamide ) within past 3 month PreTreatment monoclonal antibody ( natalizumab , rituximab ) within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Dexrazoxane</keyword>
	<keyword>Cardioxane</keyword>
	<keyword>cardiotoxicity</keyword>
	<keyword>cardiac toxicity</keyword>
	<keyword>cardiotoxic side effect</keyword>
	<keyword>cardiac MRI</keyword>
	<keyword>cranial MRI</keyword>
	<keyword>LVEF</keyword>
	<keyword>neurological outcome</keyword>
</DOC>